老年银屑病患者系统治疗的有效性与安全性:系统综述
结果显示甲氨蝶呤、环孢素等传统药物及生物制剂在老年患者中均有疗效,但数据有限且传统药物研究质量低。年龄不应成为治疗限制因素,需关注合并症、用药剂量及监测。
要点
- 老年银屑病患者使用系统治疗有效,年龄本身不应限制治疗选择。
- 环孢素与肾功能恶化相关,富马酸酯与淋巴细胞减少相关(HR 2.42)。
- 生物制剂最常见不良事件为感染,但未发现与年龄显著相关。
核心结论
- 基于有限证据,年龄本身不应成为银屑病管理的限制因素。
- 需关注合并症和合并用药,并适当调整剂量及频繁监测。
研究设计与样本
- 系统综述,检索Embase、MEDLINE和CENTRAL(截至2019年11月11日),无日期限制。
主要发现
- 诱导期(治疗开始后12-16周)PASI 75应答率:甲氨蝶呤49%(74例)、环孢素46%-52.6%(178例)、阿维A 27%-47.8%(108例)、依那西普15.6%-64%(256例)、英夫利西单抗66.7%-93%(43例)、阿达木单抗60.7%-65%(100例)、乌司奴单抗56.5%(46例)、司库奇尤单抗86.4%(67例)。
- 阿维A、依那西普、阿达木单抗和司库奇尤单抗的疗效似乎与年龄无关。
- 生物制剂使用者中最常见不良事件为感染,但未发现与年龄显著相关。
关键数值与推荐
- 纳入标准:评估65岁及以上患者系统抗银屑病治疗有效性(或疗效)和/或安全性的研究。
- 排除标准:未明确报告。
临床怎么用
- 老年银屑病患者选择系统治疗时不应仅因年龄而排除。
- 需评估合并症和合并用药,适当调整剂量并定期进行实验室和临床监测。
局限性
- 每种系统药物可用的数据有限。
- 传统系统治疗的研究总体质量低。
- 需要更多真实世界证据和前瞻性队列研究的亚组分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Treating older adults with psoriasis can be challenging owing to comorbidities, concomitant medication use, and consequent safety risks. Although many studies focus on the effectiveness and safety of systemic antipsoriatic therapies in the general population, their effectiveness in older adults with psoriasis has not been systematically assessed. OBJECTIVE: To evaluate the effectiveness and safety of systemic antipsoriatic therapies in patients 65 years or older. EVIDENCE REVIEW: A systematic literature search was conducted in Embase, MEDLINE, and the Cochrane Central Register of Controlled Trials (CENTRAL) on November 11, 2019. No date limit was used. Randomized clinical trials, cohort studies, large case series, and meta-analyses assessing efficacy (or effectiveness) and/or safety of systemic antipsoriatic therapies in patients 65 years or older were included. FINDINGS: The initial search yielded 11 096 results, of which 31 unique articles with 39 561 patients were included in analysis. Overall, limited data were available per systemic agent, and overall quality of the included studies on conventional systemic therapies was low. At the end of the induction phase (12-16 weeks after start of treatment), a reduction of 75% in Psoriasis Area and Severity Index was achieved in 49% of 74 methotrexate sodium users 65 years or older, 46% to 52.6% of 178 older cyclosporin users, 27% to 47.8% of 108 older acitretin users, 15.6% to 64% of 256 etanercept users 65 years or older, 66.7% to 93% of 43 infliximab users 65 years or older, 60.7% to 65% of 100 adalimumab users 65 years or older, 56.5% of 46 ustekinumab users 65 years or older, and 86.4% of 67 secukinumab users 65 years or older. Effectiveness of acitretin, etanercept, adalimumab, and secukinumab appeared not to be associated with age; studies regarding other systemic antipsoriatic therapies did not provide age group comparisons. Older age was significantly associated with renal function deterioration in cyclosporin users and with lymphopenia in fumaric acid esters users (hazard ratio, 2.42; 95% CI, 1.65-3.55; P < .001). Infections were the most frequently reported adverse event in patients 65 years or older using biologics, but no significant association with age was found. CONCLUSIONS AND RELEVANCE: On the basis of limited available evidence, age alone should not be a limiting factor in psoriasis management. Awareness of comorbidities and concomitant medication use is very important, as well as appropriate dosing and frequent laboratory and clinical monitoring. More real-world evidence and (sub)analyses of prospective cohort studies on the effectiveness and safety of systemic therapies in older adults are critical to optimize personalized, effective, and safe antipsoriatic management in this growing patient group.
引用
- van Winden MEC, van der Schoot LS, van de L'Isle Arias M, et al. Effectiveness and Safety of Systemic Therapy for Psoriasis in Older Adults: A Systematic Review. JAMA Dermatol. 2020. PMID: 32822455. doi:10.1001/jamadermatol.2020.2311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。